HYDERABAD, INDIA (September 25, 2008) – Suven Life Sciences Ltd, a Drug Discovery and development company announced today that they received permission from Drug Controller General of India (DCGI) to conduct Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a non-peripheral, CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia.
SUVN-502 is the lead compound, selected from a series of more than 500 compounds, which were innovatively designed and developed using the combination of traditional and rational medicinal chemistry approaches.
Suven is also in discussions for potential licensing partners for this compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets. The Company targets launching the molecule in 2012 and aims to be an early launcher in this class. Other molecules in the same category currently under development include GSK’s molecule presently in Phase II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease. Parkinson’s disease and obesity are in addition to developmental candidates in Alzheimer’s disease and Schizophrenia.
